Article

Atorvastatin induction of VEGF and BDNF promotes brain plasticity after stroke in mice.

Department of Neurology, Henry Ford Health Sciences Center, Detroit, Michigan 48202, USA.
Journal of Cerebral Blood Flow & Metabolism (Impact Factor: 5.34). 03/2005; 25(2):281-90. DOI: 10.1038/sj.jcbfm.9600034
Source: PubMed

ABSTRACT Molecular mechanisms underlying the role of statins in the induction of brain plasticity and subsequent improvement of neurologic outcome after treatment of stroke have not been adequately investigated. Here, we use both in vivo and in vitro studies to investigate the potential roles of two prominent factors, vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF), in mediating brain plasticity after treatment of stroke with atorvastatin. Treatment of stroke in adult mice with atorvastatin daily for 14 days, starting at 24 hours after MCAO, shows significant improvement in functional recovery compared with control animals. Atorvastatin increases VEGF, VEGFR2 and BDNF expression in the ischemic border. Numbers of migrating neurons, developmental neurons and synaptophysin-positive cells as well as indices of angiogenesis were significantly increased in the atorvastatin treatment group, compared with controls. In addition, atorvastatin significantly increased brain subventricular zone (SVZ) explant cell migration in vitro. Anti-BDNF antibody significantly inhibited atorvastatin-induced SVZ explant cell migration, indicating a prominent role for BDNF in progenitor cell migration. Mouse brain endothelial cell culture expression of BDNF and VEGFR2 was significantly increased in atorvastatin-treated cells compared with control cells. Inhibition of VEGFR2 significantly decreased expression of BDNF in brain endothelial cells. These data indicate that atorvastatin promotes angiogenesis, brain plasticity and enhances functional recovery after stroke. In addition, VEGF, VEGFR2 and BDNF likely contribute to these restorative processes.

0 Bookmarks
 · 
87 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Pathophysiological conditions such as cerebral ischemia trigger the production of new neurons from the neurogenic niche within the subgranular zone (SGZ) of the dentate gyrus. The functional significance of ischemia-induced neurogenesis is believed to be the regeneration of lost cells, thus contributing to post-ischemia recovery. However, the cell signaling mechanisms by which this process is regulated are still under investigation. Here, we investigated the role of mitogen and stress-activated protein kinases (MSK1/2) in the regulation of progenitor cell proliferation and neurogenesis after cerebral ischemia. Using the endothelin-1 model of ischemia, wild-type (WT) and MSK1(-/-)/MSK2(-/-) (MSK dKO) mice were injected with BrdU and sacrificed 2days, 4weeks, or 6weeks later for the analysis of progenitor cell proliferation, neurogenesis, and neuronal morphology, respectively. We report a decrease in SGZ progenitor cell proliferation in MSK dKO mice compared to WT mice. Moreover, MSK dKO mice exhibited reduced neurogenesis and a delayed maturation of ischemia-induced newborn neurons. Further, structural analysis of neuronal arborization revealed reduced branching complexity in MSK dKO compared to WT mice. Taken together, this dataset suggests that MSK1/2 plays a significant role in the regulation of ischemia-induced progenitor cell proliferation and neurogenesis. Ultimately, revealing the cell signaling mechanisms that promote neuronal recovery will lead to novel pharmacological approaches for the treatment of neurodegenerative diseases such as cerebral ischemia. Copyright © 2014 IBRO. Published by Elsevier Ltd. All rights reserved.
    Neuroscience 11/2014; DOI:10.1016/j.neuroscience.2014.10.053 · 3.33 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Angiogenesis is essential for recovery from various neurovascular diseases, such as ischemic stroke. Previous studies have revealed the regulatory role of MicroRNAs in angiogenesis in various types of cancer cells. However, the role of miR-487b in angiogenesis and how it regulates the angiogenic process of endothelial cells remain unclear. In this study, we found miR-487b was up-regulated in the plasma of ischemic stroke patients. Further, over-expression of miR-487b enhanced cell proliferation, migration, invasion and tube formation in human umbilical vein endothelial cells. Using bioinformatic analysis, we found a putative binding site of miR-487b in the 3' untranslated regions of Thrombospondin 1 mRNA, an endogenous inhibitor of angiogenesis. This direct binding was confirmed by luciferase assay. These results demonstrate that miR-487b regulates angiogenesis by directly targeting THBS1 in HUVECs, indicating that miR-487b may contribute to angiogenesis and the functional recovery from ischemic stroke. miR-487b could represent a potential therapeutic option for neurovascular disease. Copyright © 2015. Published by Elsevier Ireland Ltd.
    Neuroscience Letters 02/2015; 591. DOI:10.1016/j.neulet.2015.02.002 · 2.06 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aims of this study was to assessed the ability of a combination treatment of bone marrow stromal cell (BMSC) and atorvastatin in a rat model of spinal cord injury (SCI) as an appropriate substitute for current SCI treatments. In the present study, the female Wistar rats were divided into five groups (n = 20) after SCI by New York University Device: SCI, sham, atorvastatin, graft BMSC and graft BMSC plus atorvastatin. Locomotion was assessed using Basso, Beattie and Bresnahan (BBB) test and walking test after SCI. In addition, microvessel density (MVD) was calculated by immunohistochemistry after SCI. We also investigate the vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF) expression level by western blot after drug treatment. The results showed that BBB scores and walking test were increased in atorvastatin plus BMSC group compared to single atorvastatin and BMSC groups (P < 0.05). In addition, MVD also significantly increased in combination group compared to single treatment group. Compared to sole drug, VEGF and BDNF expression were significantly up-regulated in atorvastatin combination with BMSC group (P < 0.05). These results imply that the combined use of atorvastatin and BMSC treatment may represent a promising strategy for clinically applicable pharmacological therapy for initiation of neuroprotection after SCI.
    International Journal of Clinical and Experimental Medicine 01/2014; 7(12):4967-74. · 1.42 Impact Factor

Full-text (2 Sources)

Download
58 Downloads
Available from
May 22, 2014